Table 2 Headache incidences registered during randomized controlled trials (RCT) and open label clinical trials with pinacidil
From: The KATP channel in migraine pathophysiology: a novel therapeutic target for migraine
Paper | Study design | Dose (daily) | Indication | No. of patients | Headache No. |
|---|---|---|---|---|---|
Muiesan et al. 1985, Eur. J. Clin. Pharmacol [86]. | RCT | 30–75 mg | Essential hypertension | 30 | 2 (7%) |
Laher & Hickey 1985, J. Int. Med. Res [87]. | Open label | 12.5Â mg | Healthy volunteers | 12 | 1 (8%) |
D’Arcy et al. 1985, Eur. J. Clin. Pharmacol [88]. | Open label | 20–100 mg | Essential hypertension | 23 | 4 (17%) |
Zachariah et al. 1986, Eur. J. Clin. Pharmacol [89]. | RCT | 62Â mg (mean) | Essential hypertension | 23 | ---- |
Sterndorff & Johansen 1988, Acta Med. Scand [90]. | RCT | 25–100 mg | Essential hypertension | 71 | 7 (10%) |
Goldberg 1988, J. Cardiovasc. Pharmacol [91]. | RCT | 25–100 mg | Essential hypertension | 145 | 31 (21%) |